Studies on cell-mediated immunity in patients with malignant tumor. Part II. Leukocyte migration inhibition test in patients with malignant lymphoma.

Three different procedures of the leukocyte migration inhibition test(LMIT) were performed in order to study cell-mediated immunity in patients with malignant lymphoma. Using sonicated antigens from normal lymphocytes and lymphoma cells obtained by lymphnode biopsy, leukocytes from patients with malignant lymphoma showed a positive reaction exclusively against antigens obtained from malignant lymphoma cells. It was suggested that patients with malignant lymphoma had a cell-mediated immunity against the tumor-associated antigens. The migration index of LMIT using autochthonous antigen was significantly lower than that using allogeneic antigen. In LMITs using 3M KCI extracts of established lymphoid cell lines, it was suggested that there were both tumor-associated antigens and leukemia-lymphoma associated antigens in the extracts. The serum immuno-suppressive factor was positive in 40 of 50 patients' sera(80%) in LMITs. The suppressive ratio and immune complex levels of the sera from patients with extensive disease was significantly higher than that of patients with localized disease. Studies on cell-mediated immunity in patients with malignant tumor